• news.cision.com/
  • CS MEDICA A/S/
  • CS MEDICA A/S Enters New Partnership with Award-Winning OTC Company Holding a Strong Position in the Chronic Pain Segment in Germany
English

CS MEDICA A/S Enters New Partnership with Award-Winning OTC Company Holding a Strong Position in the Chronic Pain Segment in Germany

Report this content

CS MEDICA A/S Accelerates European Expansion by Launching 10T Innovative Pain Patches in its Main Territory.

CS MEDICA A/S, a MedTech innovator in cannabinoid-infused treatments, has entered a partnership with an undisclosed fast-growing, award-winning German OTC company. This company holds a strong position in the chronic pain segment in German pharmacies and is actively seeking innovative products to expand its own-labeled CBD portfolio. The collaboration will start with the MDR-compliant medical device; the Pain Patch, with the first 10.000 (10T) units ordered—more products are likely to be added later. The Pain Patch's launch is scheduled for Q3-2024. Detailed information will be published on launch day.

This partnership underscores CS MEDICA's strategic focus on Europe with Germany, a key market due to its size and maturity for CBD-infused products, mirroring the growing interest in the UK, Italy, and other EU markets. With this launch, CS MEDICA extends its commitment to providing natural, science-based, and effective health solutions. Additionally, the expedited process from initial contact to a paid invoice in just nine days is a testament to the company's market responsiveness and improved efficiency.

For further insights into CS MEDICA and the innovative Pain Patch, please visit https://www.cs-medica.com/ and https://www.cannasen.com/product/pain-patch 

For more information about CS MEDICA, please contact:
Gitte Lund Henriksen, CFO
Phone: + (45) 2774 2280
Email: glh@cs-medica.com
Website: https://www.cs-medica.com/

CS MEDICA, a Danish MedTech pioneer, specializes in developing evidence-based, CBD-integrated treatments for pain management, autoimmune and stress-related disorders. With a focus on patient-centric care, our products range from innovative R&D to registered over-the-counter substance-based medical devices and dermaceuticals. Our flagship CANNASEN® brand, alongside our own-label solutions, exemplifies our dedication to safe, high-quality treatments for both human and veterinary health globally.

The company is listed on Spotlight Stock Market in Stockholm (symbol: “CSMED”). For more information, visit cs-medica.com and LinkedIn.

Tags:

OTC Pain relief medical device pain management CBD MDR PAIN PATCH GERMAN MARKET OWN LABEL

Subscribe

Documents & Links

Quick facts

CS MEDICA has entered a partnership with an undisclosed fast-growing, award-winning German OTC company. This company holds a strong position in the chronic pain segment in German pharmacies and is actively seeking innovative products to expand its own-labeled CBD portfolio.
Tweet this
This partnership underscores CS MEDICA's strategic focus on Europe with Germany, a key market due to its size and maturity for CBD-infused products, mirroring the growing interest in the UK, Italy, and other EU markets.
Tweet this
The expedited process from initial contact to a paid invoice in just nine days is a testament to the company's market responsiveness and improved efficiency.
Tweet this